Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)-Reference-Cited by-同舟云学术

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

Published:2006-01 Issue:2 Volume:24 Page:154-159
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Hebbar Mohamed,Tournigand Christophe,Lledo Gérard,Mabro May,André Thierry,Louvet Christophe,Aparicio Thomas,Flesch Michel,Varette Charles,de Gramont Aimery,Group (GERCOR) Oncology Multidisciplinary Research

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/07357900500524397

Reference34 articles.

1. New systemic frontline treatment for metastatic colorectal carcinoma

2. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

3. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

4. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

5. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801);International Journal of Clinical Oncology;2015-06-03

2. Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701);Oncology;2013

3. Successful Management with Splenectomy for Splenomegaly with Thrombocytopenia and Leukocytopenia Caused by Oxaliplatin-based Chemotherapy for Metastatic Colon Cancer. A Case Report;Nippon Daicho Komonbyo Gakkai Zasshi;2013

4. Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases;International Journal of Colorectal Disease;2012-12-15

5. Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy;Clinical & Experimental Metastasis;2012-11-27